Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 4, 2006, Pages 442-445

  Akay, B N ^a   Ekmekci, P ^a   Sanli, H ^a   Celik, G ^a   Bozdayi, M ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Chronic hepatitis C; Interferon alpha; Sarcoidosis

Indexed keywords

ALPHA INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; LABORATORY DIAGNOSIS; LIVER BIOPSY; LIVER DISEASE; LUNG SARCOIDOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERODIAGNOSIS; SKIN BIOPSY; SKIN DISEASE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPOTHYROIDISM; INTERFERON-ALPHA; MIDDLE AGED; SARCOIDOSIS; THROMBOCYTOPENIA;

EID: 33645352511     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01450.x     Document Type: Article

References (29)

1. Sacchi S, Kantarjian H, O'Brien S et al. Immune-mediated and unusual complications during IFN-α therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401-2407.
2. Agostini C, Basso U, Semenzato G. Cells and molecules involved in the development of sarcoid granuloma. J Clin Immunol 1998; 88: 184-192.
3. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 24-31.
4. Moller DR. Etiology of sarcoidosis. Clin Chest Med 1997; 18: 695-706.
5. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983; 308: 793-800.
6. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-1495.
7. Fels AOS,Nathan DF,Cohn ZA. Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3. J Clin Invest 1987; 80: 381-386.
8. Abdi E, Nguyen G, Ludwig R, Dickout W. Pulmonary sarcoidosis following IFN therapy for advanced renal cell carcinoma. Cancer 1987; 59: 896-900.
9. Hoffmann RM, Jung MC, Motz R et al. Sarcoidosis associated with IFN (therapy for chronic hepatitis C). J Hepatol 1998; 28: 1058-1063.
10. Kikawada M, Ichinose Y, Kunisawa A et al. Sarcoidosis induced by IFN therapy for chronic myelogenous leukemia. Respirology 1998; 3: 41-44.
11. Wandl UB, Kloke O, Nagel-Hiemke M et al. Combination therapy with IFN-alpha 2b plus low dose IFN-gamma in pretreated patients with PH-positive chronic myelogenous leukemia. Br J Haematol 1992; 81: 516-519.
12. Yavorkovski LL, Carrum G, Bruce S, McCarthy P. Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with IFN. Am J Hematol 1998; 58: 80-81.
13. Pohl J, Stremmel W, Kallinowski B. Pulmonary sarcoidosis. A rare side effect of IFN treatment for chronic hepatitis C infection. Z Gastroenterol 2000; 38: 951-955.
14. Frankova H, Gaja A, Hejlova N. Pulmonary sarcoidosis in a patient with essential thrombocytopenia treated with IFN-alpha. Med Sci Monit 2000; 6: 380-382.
15. Pietropaoli A, Modrak J, Utell M. IFN therapy associated with the development of sarcoidosis. Chest 1999; 116: 569-572.
16. Neglia V, Sookoian S, Herrera M, Abeldano A. Development of cutaneous sarcoidosis in a patient with chronic hepatitis C treated with interferon alpha 2b. J Cutan Med Surg 2001; 5: 406-408.
17. Cacoub P, Sbai A, Frances C, Genesti C. Systemic sarcoidosis during interferon alpha therapy for chronic hepatitis C virus infection. Gastroenterol Clin Biol 2000; 24: 364-366.
18. Michavila AI, Sanchez MM, Ronchel PJ et al. Sarcoidosis following combined ribavirin and interferon therapy: A case report and review of the literature. Arch Bronconeumol 2004; 40: 45-49.
19. Quasada JR, Talpaz M, Rios A et al. Clinical toxicity of IFN in cancer patients: A review. J Clin Oncol 1986; 4: 234-243.
20. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high dose IFN therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
21. Conlon KC, Urba WJ, Smith JW et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha IFN therapy. Cancer 1990; 65: 2237-2242.
22. Rizzi R, Lucarella FP, Ruggieri GB, L'Abbate M. Autoimmune hemolytic anemia presenting during treatment of chronic hepatitis C with interferon alpha. Ann Ital Med Int 2003; 18: 107-110.
23. Fujii H, Kitada T, Yamada T et al. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology 2003; 50: 841-842.
24. Parana R, Cruz M, Santos-Jesus R et al. Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin. Braz J Infect Dis 2000; 4: 284-290.
25. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31: 210-216.
26. Wang CS, Yao WJ, Wang ST et al. Strong association of hepatitis C virus infection and thrombocytopenia; implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004; 39: 790-796.
27. Medeiros B, Seligman P, Everson G, Forman L. Possible autoimmune thrombocytopenia associated with pegylated interferon alpha-2a plus Ribavirin treatment for hepatitis C. J Clin Gastroenterol 2004; 38: 84-86.
28. Zuckerman E, Yeshurun D, Rosner I. Management of hepatitis C virus-related arthritis. Biodrugs 2001; 15: 573-584.
29. Bonnet F, Morlat P, De Witte S, Bonarek M. Sarcoidosis-associated hepatitis C virus infection. Dig Dis Sci 2002; 47: 794 -796.